Llwytho...
Systemic treatment for metastatic prostate cancer
The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy (docetaxel, cabazitaxel), new hormonal therapies (a...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Asian J Urol |
|---|---|
| Prif Awdur: | |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Second Military Medical University
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6488732/ https://ncbi.nlm.nih.gov/pubmed/31061802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajur.2019.02.002 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|